Clinical Trial Update: Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy [Phase 1, Phase 2]

View source ↗

Summary

Ocugen is conducting a Phase 1/2 trial to assess the safety and efficacy of OCU410 for geographic atrophy. The study status is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Geographic Atrophy

Drugs mentioned

• OCU410

Snippet

Sponsor: Ocugen | Conditions: Geographic Atrophy | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING